Posted by Michael Wonder on 04 Jun 2018
Apotex builds momentum in Canada's biosimilar market after world's first approval
1 June 2018 - Health Canada leads the way by approving the first-ever pegfilgrastim biosimilar in any highly regulated world market
Apobiologix, a division of Apotex, further bolstered its leadership in Canada’s growing biosimilar market. The company that is focused on the development of biosimilars for global markets, recently received approval from Health Canada for Apobiologix’s latest product addition, Lapelga.
The recent Health Canada approval is a noteworthy success for Apobiologix as this is the first-ever pegfilgrastim biosimilar approved in any highly regulated market worldwide.
